Fig 1.
Flowchart of Patient Evaluation By Strategy.
Table 1.
Estimates of Test Performance and Disease Prevalence for the Model.
Fig 2.
A Simplified Depiction of the Microsimulation State-Transition Model.
HCC = Hepatocellular carcinoma; NAFLD = Nonalcoholic Fatty Liver Disease; NASH = Nonalcoholic Steatohepatitis.
Table 2.
The Cost and Effect of Non-invasive Evaluations of Nonalcoholic Fatty Liver Disease (NAFLD) Compared to Usual Care (Liver Biopsy) in the Primary Care and Referral Setting.
Table 3.
Strategy Performance in a cohort of 10,000 patients.